海思科涨2.04%，成交额1620.64万元，主力资金净流出43.16万元

Core Viewpoint - The stock of Haishike Pharmaceutical Group has shown a significant increase of 59.34% year-to-date, despite recent declines in the short term, indicating potential volatility in its stock performance [1][2]. Group 1: Stock Performance - As of December 19, Haishike's stock price rose by 2.04% to 52.55 CNY per share, with a total market capitalization of 58.852 billion CNY [1]. - The stock has experienced a decline of 3.93% over the last five trading days, 6.48% over the last 20 days, and 4.02% over the last 60 days [1]. - The net outflow of main funds was 431,600 CNY, with large purchases amounting to 1.5072 million CNY, accounting for 9.30% of total transactions, while sales reached 1.9389 million CNY, making up 11.96% [1]. Group 2: Financial Performance - For the period from January to September 2025, Haishike reported a revenue of 3.3 billion CNY, reflecting a year-on-year growth of 19.95%, while the net profit attributable to shareholders decreased by 22.66% to 295 million CNY [2]. - Cumulatively, the company has distributed 3.673 billion CNY in dividends since its A-share listing, with 687 million CNY distributed over the past three years [3]. Group 3: Shareholder Information - As of September 30, 2025, the number of shareholders increased by 12.87% to 12,900, with an average of 37,342 circulating shares per person, a decrease of 11.40% [2]. - The top ten circulating shareholders include various funds, with notable increases in holdings by Central European Medical Health Mixed A and Hong Kong Central Clearing Limited [3].